Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 4/20 | 0.58 |
| ▸ | ACE | P12821 | 7/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.51 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.51 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.49 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL121370 | 1.00 | MME (0.58) | MMEACEALDH1A1FOLH1NAALAD2 | |
| SCHEMBL6716497 | 1.00 | MME (0.58) | MMEACEALDH1A1FOLH1NAALAD2 | |
| SCHEMBL11346818 | 1.00 | MME (0.58) | MMEACEALDH1A1FOLH1NAALAD2 | |
| SCHEMBL6065430 | 1.00 | MME (0.58) | MMEACEALDH1A1FOLH1NAALAD2 | |
| SCHEMBL8414223 | 0.95 | FOLH1 (0.55) | MMEACEALDH1A1FOLH1NAALAD2 | |
| SCHEMBL148423 | 0.95 | FOLH1 (0.55) | MMEACEALDH1A1FOLH1NAALAD2 | |
| SCHEMBL73955 | 0.92 | MME (0.56) | MMEALDH1A1FOLH1NAALAD2PSMB5 | |
| SCHEMBL11581853 | 0.92 | MME (0.56) | MMEALDH1A1FOLH1NAALAD2PSMB5 | |
| SCHEMBL497336 | 0.92 | MME (0.56) | MMEALDH1A1FOLH1NAALAD2PSMB5 | |
| Dl-Phenylalanine SCHEMBL28118724 | 0.92 | SLC7A5 (0.65) | MMEACESLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023245852-A1 | CD25 TARGETING POLYPEPTIDE, MOLECULAR PROBE AND USE | 北京肿瘤医院(北京大学肿瘤医院) | 2023-12-28 | — | — | WO | claimed |
| CN-110637007-B9 | Synthesis of tyrosine-derived diphenol monomers | 美敦力公司 | 2023-08-15 | — | — | CN | claimed |
| CN-110637007-B | Synthesis of tyrosine-derived diphenol monomers | 美敦力公司 | 2023-06-16 | — | — | CN | claimed |
| CN-114773433-A | CD25 targeted polypeptide, molecular probe and application | 北京肿瘤医院(北京大学肿瘤医院) | 2022-07-22 | — | — | CN | claimed |
| EP-2922559-B1 | SYNTHETIC LINEAR APELIN MIMETICS FOR THE TREATMENT OF HEART FAILURE | NOVARTIS AG (CH) | 2018-10-10 | — | — | EP | claimed |
| US-10005829-B2 | Synthetic linear apelin mimetics for the treatment of heart failure | NOVARTIS AG (CH) | 2018-06-26 | — | — | US | claimed |
| CN-105007928-A | Synthetic linear apelin mimetics for the treatment of heart failure | NOVARTIS AG | 2015-10-28 | — | — | CN | claimed |
| US-20150284446-A1 | SYNTHETIC LINEAR APELIN MIMETICS FOR THE TREATMENT OF HEART FAILURE | NOVARTIS AG (CH) | 2015-10-08 | — | — | US | claimed |
| EP-2922559-A2 | SYNTHETIC LINEAR APELIN MIMETICS FOR THE TREATMENT OF HEART FAILURE | Novartis AG (CH) | 2015-09-30 | — | — | EP | claimed |
| US-8921307-B2 | Synthetic linear apelin mimetics for the treatment of heart failure | NOVARTIS AG (SE) | 2014-12-30 | — | — | US | claimed |
| US-20140155315-A1 | SYNTHETIC LINEAR APELIN MIMETICS FOR THE TREATMENT OF HEART FAILURE | NOVARTIS AG (CH) | 2014-06-05 | — | — | US | claimed |
| WO-2014081702-A2 | SYNTHETIC LINEAR APELIN MIMETICS FOR THE TREATMENT OF HEART FAILURE | NOVARTIS AG (CH) | 2014-05-30 | — | — | WO | claimed |
| EP-1109831-B1 | CYCTOTOXIC PEPTIDES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES | LYTIX BIOPHARMA AS (NO) | 2011-01-12 | — | — | EP | claimed |
| US-7736630-B2 | Products for preventing penetration into the skin | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2010-06-15 | — | — | US | claimed |
| EP-1029073-A1 | METHOD AND AGENT FOR DETERMINING AN ENZYMATIC ACTIVITY SUCH AS DEAMINASE | BIO MERIEUX (FR) | 2000-08-23 | — | — | EP | claimed |
| WO-1999024604-A1 | METHOD AND AGENT FOR DETERMINING AN ENZYMATIC ACTIVITY SUCH AS DEAMINASE | BIO MERIEUX (FR) | 1999-05-20 | — | — | WO | claimed |
| EP-0370454-A2 | Renin-inhibiting amino diol derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-05-30 | — | — | EP | claimed |
| US-20260139053-A1 | TRISPECIFIC COMPOSITIONS COMPRISING IL-2, VEGF BINDING DOMAINS, AND PD-1 BINDING DOMAINS | BRIGHT PEAK THERAPEUTICS AG (CH) | 2026-05-21 | — | — | US | disclosed |
| US-4526719-A | Benzoquinone derivatives and production thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1985-07-02 | — | — | US | disclosed |
| US-4113713-A | PALLADIUM CATALYST | G. D. SEARLE & CO. (US) | 1978-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284446-A1 | SYNTHETIC LINEAR APELIN MIMETICS FOR THE TREATMENT OF HEART FAILURE | APLNR, AP3B1, FABP3 | MME 54/4885ACE 255/4885ALDH1A1 4583/4885 |
| US-20260139053-A1 | TRISPECIFIC COMPOSITIONS COMPRISING IL-2, VEGF BINDING DOMAINS, AND PD-1 BINDING DOMAINS | PDCD1LG2, PDCD1, IL2 | MME 4022/4885ACE 4154/4885ALDH1A1 1830/4885 |
| US-20140155315-A1 | SYNTHETIC LINEAR APELIN MIMETICS FOR THE TREATMENT OF HEART FAILURE | APLNR, AP1G1, NPY1R | MME 2586/4885ACE 647/4885ALDH1A1 2966/4885 |
| US-10005829-B2 | Synthetic linear apelin mimetics for the treatment of heart failure | APLNR, AP3B1, FABP3 | MME 54/4885ACE 255/4885ALDH1A1 4583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.